2024-03-29T15:29:10Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/149862022-09-17T01:00:51Zcom_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_2061
00925njm 22002777a 4500
dc
Alderson, Mark R
author
Arkwright, Peter D
author
Bai, Xilian
author
Black, Steve
author
Borrow, Ray
author
Caugant, Dominique A
author
Dinleyici, Ener Cagri
author
Harrison, Lee H
author
Lucidarme, Jay
author
McNamara, Lucy A
author
Meiring, Susan
author
Sáfadi, Marco A P
author
Shao, Zhujun
author
Stephens, David S
author
Taha, Muhamed-Kheir
author
Vazquez-Moreno, Julio Alberto
author
Zhu, Bingqing
author
GMI collaborators
author
2022-03
This review article incorporates information from the 4th Global Meningococcal Initiative summit meeting. Since the introduction of stringent COVID-19 infection control and lockdown measures globally in 2020, there has been an impact on IMD prevalence, surveillance, and vaccination compliance. Incidence rates and associated mortality fell across various regions during 2020. A reduction in vaccine uptake during 2020 remains a concern globally. In addition, several Neisseria meningitidis clonal complexes, particularly CC4821 and CC11, continue to exhibit resistance to antibiotics, with resistance to ciprofloxacin or beta-lactams mainly linked to modifications of gyrA or penA alleles, respectively. Beta-lactamase acquisition was also reported through horizontal gene transfer (blaROB-1) involving other bacterial species. Despite the challenges over the past year, progress has also been made on meningococcal vaccine development, with several pentavalent (serogroups ABCWY and ACWYX) vaccines currently being studied in late-stage clinical trial programmes.
J Infect. 2022 Mar;84(3):289-296.
http://hdl.handle.net/20.500.12105/14986
34838594
10.1016/j.jinf.2021.11.016
1532-2742
The Journal of infection
Antibiotic resistance
COVID-19
Coronavirus
Invasive meningococcal disease
Neisseria meningitidis
Pandemic
Serogroup
Sexual transmission
Vaccination
Surveillance and control of meningococcal disease in the COVID-19 era: A Global Meningococcal Initiative review